AURORA-A is a mitotic kinase that is essential for cell cycle progression,27 whilst FAK plays important roles in tumour progression and metastasis.28 Several FAK-targeting PROTACs have been reported and some showed anti-cancer therapeutic potential thanks to the elimination of the non-enzymatic functions of FAK.29 In addition to introducing a new class of photoswitch for light-responsive PROTACs, this work suggests opportunities for future development of multi-targeted degraders with readily available promiscuous inhibitors to achieve enhanced or synergistic target degradation. The gene discussed is PTK2; the disease is cancer.